@article {2309, title = {Synergistic Effect of Imperata cylindrica Root Extract and Erlotinib on A549 Lung Cancer Cell Viability}, journal = {Pharmacognosy Journal}, volume = {16}, year = {2024}, month = {June 2024}, pages = {656-659}, type = {Research Article}, chapter = {656}, abstract = {

Background: Erlotinib is typically used to treat lung adenocarcinoma and Imperata cylindrica extract has been shown to exert anti-cancer effects in various human cancer cell lines. Therefore, this study evaluated the combined anticancer effects of Imperata cylindrica ethanol root extract and erlotinib on the A549 lung cancer cell line. Method: The A-549 lung cancer cell line was treated with various combinations of 1/2 IC50, 3/8 IC50, 1/4 IC50, and 1/8 IC50 of I.cylindrica root ethanol extract and erlotinib for 48 hours. Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, analyzed and interpreted using CompuSyn software and a normalized isobologram curve. Result: Of the sixteen combinations, eleven combinations acted synergistically, four were additive, and one was in the antagonist zone. Conclusion: The combination of I. cylindrica root ethanol extract and erlotinib act synergistically to decrease A549 lung cancer cell viability, therefore they are potential lung cancer therapeutics.

}, keywords = {A549, Cell viability, Erlotinib, Imperata cylindrica}, doi = {10.5530/pj.2024.16.103}, author = {Raden Anita Indriyanti and Eko Fuji Ariyanto and Hermin Aminah Usman and Ristaniah Rose Effendy and Diah Dhianawaty} } @article {1958, title = {The effect of Sinensetin and Imperatorin on A-549 lung cancer cell viability in vitro}, journal = {Pharmacognosy Journal}, volume = {15}, year = {2023}, month = {March 2023}, pages = {38-46}, type = {Original Article }, chapter = {38}, abstract = {

Introduction: Lung cancer remains the leading cause of cancer death worldwide, so research is ongoing to discover new therapeutics, such as plant-derived bioactive compounds. For example, Sinensetin, a plant-derived polymethoxylated flavonoid, and Imperatorin, a natural furanocoumarin, have anti-cancer properties. This study assessed the effects of sinensetin and imperatorin separately and in combination on A-549 lung cancer cell viability. Method: The A-549 lung cancer cell line was treated with sinensetin (60 μM), imperatorin (30 M), or a combination of both compounds (Sin:Imp 30:30 μM; 50:50 μM and 60:30 μM) for 48 hours. Cell viability was then assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) assay and apoptosis was determined using fluorescein isothiocyanate (FITC) Annexin-V/Propidium iodide staining. Results: The combination treatment of Sin:Imp 50:50 and Sin:Imp 60:30 μM reduced cell viability more than the individual treatment of sinensetin and imperatorin, with the lowest cell viability observed for the combination treatment of Sin:Imp 50:50 μM. Likewise, the combination treatment of Sin:Imp 50:50 μM induced the most apoptosis compared to individual treatment. Conclusion: Sinensetin and imperatorin can decrease A-549 lung cancer cell viability and are potent apoptotic inducers, especially when they are used in combination, therefore they are potential lung cancer therapeutics.

}, keywords = {A549, Apoptosis, Cell viability, Imperatorin, Sinensetin}, doi = {10.5530/pj.2023.15.6}, author = {Raden Anita Indriyanti and Eko Fuji Ariyanto and Hermin Aminah Usman and Ristaniah Rose Effendy and Diah Dhianawaty} } @article {1147, title = {Screening Data Reveals that Spirogyra triplicata, a Fresh Water Algae Induces Robust Anti-Proliferative Activity Against A549 Cells}, journal = {Pharmacognosy Journal}, volume = {12}, year = {2020}, month = {May 2020}, pages = {569-577}, type = {Research Article}, chapter = {569}, abstract = {

Introduction: Algae comprise a promising source of novel components with potent therapeutic agents. In particular, algae have been considered as a potential source of new bioactive compounds. The antioxidant data of our previous study with six different algal methanolic extract reveals the presence of high antioxidant, total phenol content and total flavonoid content in Spirogyra triplicata. Thus, we further focused on screening the anti-proliferative activity of six different green algae on five different cancer cell lines like MCF7, A549, HEPG2, REH, MOLT4. Methods: To fulfill our aim we performed MTT assay for testing anti-proliferative activity and DAPI staining for observing nuclear morphology. We also looked into the metabolomic profiling of Spirogyra triplicata by GC-MS chemometric study. Results: The result indicates that after 24 hours of treatment with methanolic extract of Spirogyra triplicata A549 was the most sensitive cell line with IC50 value of 24.07 {\textpm} 1.09 μg/ml. Followed by Rhizoclonium fontinale and Hydrodictyon reticulatum with IC50 value of 25.97 {\textpm} 1.94 μg/ml and 32.50 {\textpm} 1.97 μg/ml respectively. The HEPG2 cell line was the second most sensitive cell line against S. triplicata with IC50 value of 30.20 {\textpm} 1.45 μg/ml. The MOLT4 cell line was detected as most resistant cell line against the green algal extract in this study. Though the methanolic extracts of six green algae showed maximum to moderate anti-proliferative activity on different cancer cell line but no significantly affect on normal PBMC was observed. Nuclear fragmentation was observed in a dose dependent fashion by DAPI staining on A549 cells treated with methanolic extract of Spirogyra triplicata. We further looked into the chemo profiling of Spirogyra triplicata by GCMS analysis. The result of GC-MS clearly indicates presence of nineteen major components and twenty-three minor components which have more or less bioactivity and would help in therapeutics in future. Conclusions: In brief this study indicates for the first time that green algae Spirogyra triplicata induces anti-proliferative activity specifically against A549 cell but not in normal PBMC. It can be concluded that Spirogyra triplicata holds a great promise as a good repository of anti cancer compounds which may be used in future drug discovery.

}, keywords = {A549, Anti-proliferative, GCMS, Spirogyra triplicata}, doi = {10.5530/pj.2020.12.86 }, author = {Ankita Mridha and Priya K Gopal and Santanu Paul} }